Journal: PLoS ONE

Article Title: Skeletal muscle IL-6 regulates muscle substrate utilization and adipose tissue metabolism during recovery from an acute bout of exercise

doi: 10.1371/journal.pone.0189301

Figure Lengend Snippet: (h) Representative blots of HSL 565 phosphorylation, HSL, UCP1 and P38 protein content. Values are mean ± SE; (n = 9–10). *: significantly different from non-exercised within given genotype (p<0.05), ¤: significantly different from 6h within given genotype (p<0.05), #: significantly different from Control within given time point (p<0.05).

Article Snippet: Membranes were then incubated in primary antibody recognizing ACC Ser212/79 phosphorylation (#07–303, Millipore, Darmstad, Germany), AMPK Thr172 phosphorylation (#2535S, Cell Signaling, Danvers, MA, USA), AMPKα2 (Hardie, G,), GAPDH (Cell Signaling, Danvers, MA, USA), G6Pase (#sc-27198 (c14), Santa Cruz Biotechnology, Dallas TX, USA), GLUT4 (#PAI-1065, ABR), HSL Ser660 and Ser565 phosphorylation as well as HSL protein (#8334 and #8334 Cell Signaling, respectively), HKII (#2867, Cell Signaling), LDHa (#sc-27230 Santa Cruz Biotechnology), P38 Thr180/Tyr182 phosphorylation (#4511 Cell Signaling), P38 (#9212, Cell Signaling), PDH Ser300 and Ser295 phosphorylation (Hardie, G), PDH Ser232 phosphorylation (#AP1063, Calbiochem, Millipore), PDH-E1α (Hardie, G), PDK4 (Hardie, G), PEPCK (#10004943, Cayman chemicals, Elsworth, MI, USA), or UCP1 (#AB10983, Abcam, Cambridge, UK) overnight.

Techniques: Phospho-proteomics, Control

Journal: PLoS ONE

Article Title: Skeletal muscle IL-6 regulates muscle substrate utilization and adipose tissue metabolism during recovery from an acute bout of exercise

doi: 10.1371/journal.pone.0189301

Figure Lengend Snippet:

Article Snippet: Membranes were then incubated in primary antibody recognizing ACC Ser212/79 phosphorylation (#07–303, Millipore, Darmstad, Germany), AMPK Thr172 phosphorylation (#2535S, Cell Signaling, Danvers, MA, USA), AMPKα2 (Hardie, G,), GAPDH (Cell Signaling, Danvers, MA, USA), G6Pase (#sc-27198 (c14), Santa Cruz Biotechnology, Dallas TX, USA), GLUT4 (#PAI-1065, ABR), HSL Ser660 and Ser565 phosphorylation as well as HSL protein (#8334 and #8334 Cell Signaling, respectively), HKII (#2867, Cell Signaling), LDHa (#sc-27230 Santa Cruz Biotechnology), P38 Thr180/Tyr182 phosphorylation (#4511 Cell Signaling), P38 (#9212, Cell Signaling), PDH Ser300 and Ser295 phosphorylation (Hardie, G), PDH Ser232 phosphorylation (#AP1063, Calbiochem, Millipore), PDH-E1α (Hardie, G), PDK4 (Hardie, G), PEPCK (#10004943, Cayman chemicals, Elsworth, MI, USA), or UCP1 (#AB10983, Abcam, Cambridge, UK) overnight.

Techniques: Control

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Intracellular signaling response after parathyroid hormone (PTH) (A) or abaloparatide (ABL) (B) binds to the parathyroid hormone 1 receptor (PTH1R) on osteoblasts. When PTH binds to the R0 conformation of the receptor the adenyl cyclase (AC) converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), thus resulting in a prolonged increase in cAMP. In contrast to abaloparatide, which is more selective in favor of binding the RG conformation of PTH1R and thereby inducing a more temporal signaling response by a short and rapid increase in cAMP ( , , ).

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques: Binding Assay

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Number of animals, BW at study start, BW at study end, femoral length, rectus femoris muscles mass, and ionized calcium in serum of rats injected with BTX into the right hindlimb and treated with PTH or ABL.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques: Muscles, Injection

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Microstructural properties of the right femoral mid-diaphysis from rats with the right hindlimb immobilized with BTX and treated with PTH or ABL.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques:

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Microstructural properties of the right femoral epiphysis and metaphysis from rats with the right hindlimb immobilized with BTX and treated with PTH or ABL.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques:

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Distal femoral metaphyseal and epiphyseal trabecular bone parameters determined by μCT from rats with the right hindlimb immobilized with BTX and treated with PTH or ABL. (A , B) BV/TV, bone volume/tissue volume; (C , D) Tb.Th, trabecular thickness; (E , F) SMI, structure model index. Data are presented as mean ± SD. a: p < 0.05 vs. Ctrl. b: p < 0.05 vs. BTX. c: p < 0.05 vs. BTX + PTH.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques:

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Representative three-dimensional images of a 100-μm-thick slice through the distal femoral metaphysis and epiphysis from rats with the right hindlimb immobilized with BTX and treated with PTH or ABL. Metaphyseal and epiphyseal BV/TV values for the depicted bone samples; Ctrl: 38% and 44%, BTX: 24% and 33%, BTX + PTH: 34% and 41%, BTX + ABL: 31% and 39%, respectively.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques:

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Microstructural properties of L5 from rats with the right hindlimb immobilized with BTX and treated with PTH or ABL.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques:

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Fracture strength ( F max ) of the femoral mid-diaphysis (A) , femoral neck (B) , and distal femoral metaphysis (C) of rats with the right hindlimb immobilized with BTX and treated with PTH or ABL. Data are presented as mean ± SD. a: p < 0.05 vs. Ctrl. b: p < 0.05 vs. BTX.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques:

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Dynamic bone histomorphometry at the cortical femoral mid-diaphysis of rats with the right hindlimb immobilized with BTX and treated with PTH or ABL.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques:

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Dynamic bone histomorphometry on the proximal tibial metaphysis of rats with the right hindlimb immobilized with BTX and treated with PTH or ABL. (A, B) MS/BS, mineralizing surface; (C, D) MAR, mineral apposition rate; (E, F) BFR/BS, bone formation rate. Data are presented as mean ± SD. a: p < 0.05 vs. Ctrl. b: p < 0.05 vs. BTX. c: p < 0.05 vs. BTX + PTH.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques:

Journal: Frontiers in Endocrinology

Article Title: The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar

doi: 10.3389/fendo.2020.588773

Figure Lengend Snippet: Osteoblast surface and osteoclast surface at the proximal tibial metaphysis of rats with the right hindlimb immobilized with BTX and treated with PTH or ABL.

Article Snippet: Human PTH (1–34) (H-4835, Bachem, Bubendorf, Switzerland) (80 μg/kg/day) and ABL (H-8334, Bachem, Bubendorf, Switzerland) (77 μg/kg/day) was administered as s.c. injections 5 days a week to animals in the BTX + PTH and BTX + ABL groups, respectively.

Techniques: